LANTUS®(insulin glargine injection) 100 Units/mL
CLINICAL HERITAGE AND ESTABLISHED SAFETY PROFILE

There's only one Lantus®

500hcp
CLINICAL TRIALS--- AND COUNTING1

CLINICAL HERITAGE

  • 16 years of experience since FDA approval in 20002
  • As of January 2017, more than 2.3 million current patients3
  • Studied in 500 clinical trials—and counting1
PATIENTS ON LANTUS® WERE

HCP2

more likely to achieve 2 consecutive A1C levels of ≤ 6.5%4

CLINICAL RESULTS

  • Consistent A1C results: 17.5% of patients on Lantus® and 10.1% on those on OADs achieved A1C ≤ 6.5% at 2 consecutive visits (P=0.032)4
  • Efficacy with once-daily dosing5
  • Rates of severe and overall hypoglycemia were similar between Lantus® + OADs vs OAD adjustment alone (0.5% for both groups, and 48.5% vs 42.2%, respectively)4
A 24-week study of patients with T2DM randomized to start Lantus® with self-titration (n=206) or conventional therapy with physician adjustment of OADs (n=199). Patients had to be taking 0 to 2 OADs, with at least one taken at or below half maximal dose at study start. Patients could not have any substantial change in oral dose for at least 3 months before randomization.

DEMONSTRATED LONG-TERM CV SAFETY

In the landmark ORIGIN trial (N=12,537)2:
Landmark ORIGIN trial of Lantus CV events Landmark ORIGIN trial of Lantus CV events

A randomized study of patients with IFG and/or IGT or early T2DM and established CV disease or CV risk at baseline. Patients received either Lantus® (n=6264) titrated to a target FPG of ≤ 95 mg/dL or standard care (n=6273). Standard care patients remained on their original treatment, if applicable, at randomization. Additional agents could be added as needed per the discretion of the investigator. Median follow-up: 6.2 years.2,6

  • No statistically significant difference between Lantus® and standard care in the incidence of CV events. P=NS2,7

PROVEN SAFETY

  • Demonstrated long-term CV safety data–including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure2.
  • Incidence of severe hypoglycemia (5.6% Lantus® and 1.8% Standard Care)2,7